Born in November, 1949 in China. With a Bachelor’s Degree, he holds the professional title of senior engineer. He worked as the officer and Director of the Bureau of Medical Devices of the Ministry of Health. Then he served as the Director and Deputy Director General of Personnel Department, and as the Director General of the Policies and Regulations Department in China Pharmaceutical Administration. He was the Deputy General Manager of China Medical Device Industry Corporation, and the Board Secretary of China National Pharmaceutical Group Corporation (SINOPHARM). Now, he is the Executive President of China Pharmaceutical Industry Association (CPIA).

You can access his presentation here and here.

Born in Changzhou, Jiangsu Province, China, off-campus graduate supervisor of China Pharmaceutical University. As a senior engineer and licensed pharmacist, he is the Chairman & General Manager of Chang Zhou Si Yao Pharmaceuticals Co., Ltd. He is also the Vice President of CPIA. He has obtained several honored titles as an outstanding entrepreneur in China.

You can access his presentation here.

Pär Tellner is Director, Team Leader and ICH Coordinator at EFPIA since 2012. He is also in charge of the EFPIA support to the international regulatory affairs.

 Pär has previously been working as Compliance officer (marketing ethics) and Director of Veterinary Medicine, LIF Sweden and as Head of regulatory affairs for several pharmaceutical companies, e.g Octapharma, Biovitrum, Pharmacia Plasma Products and Novartis. Pär has also been working as Senior Pharmaceutical Officer for the Swedish Medical Products Agency.

Pär graduated as a pharmacist at Uppsala University in 1986.

You can access his presentation here.

Special Guest Vice President of CPIA, Director-General of Hebei Pharmaceutical Association, and Secretary of the Party Committee of Hebei Pharmaceutical Profession Association.

You can access his presentation here.

Bengt Mattson began his career in Pfizer in 1994 as Research Scientist within the Packaging Development in Stockholm, Sweden. He became Manager of Environment & Risk Management in 1995. He was named Director of ESH & EMU (Environment, Safety and Health & Engineering, Maintenance and Utilities) in 2000 and is today head of Corporate Social Responsibility & Environmental Affairs for Pfizer’s operations in Sweden. 2005 he became the chairman of the Environmental Committee of the Swedish Association of the Pharmaceutical Industry (LIF), and since 2012 he works 50% of his time at the LIF Secretariat managing sustainability matters for the association. Since Jan 2014 he is co-chair of EFPIA’s (the European Federation of Pharmaceutical Industries and Associations) task force on pharmaceuticals in the environment (PIE TF). 

Bengt has an MSc-degree in Chemical Engineering and a PhD-degree in Polymer Chemistry from the Royal Institute of Technology in Stockholm, Sweden.

Since April 2008 you can follow and discuss Bengt’s work at www.ansvarsblogg.se (the Pfizer Sweden ”Environmental and CSR blog”).

Bengt enjoys playing the violin, mainly Swedish folk music, and doing different sports with his son, Christoffer.

You can access his presentation here.

Founder, Chairman& CEO of Asymchem Group, established Asymchem in RTP, North Carolina in 1995 which has been developed into one of the top internationalized CDMOs with 13 subsidiaries and over 2,700 staffs around the world. With more than 70 patents and 18 publications of high impact factors (JOC, JACS), Dr. Hong was chosen as one of the first batch of the Thousand Talents Plan in China in May 2009, and serves as one of the distinguished experts on the National Recruitment Program of Global Experts. In January 2018, Dr. Hong was elected to be the Vice President of China Pharmaceutical Industry Association (CPIA).

Born in 1962, senior engineer with principal senior professional title. He is now the General Manager of North China Pharmaceutical Group Corporation, the expert obtaining the special allowance of the State Council, one of Hebei’s Outstanding Experts. For all these years, he devotes himself to the management of pharmaceutical enterprises, and the application and studies of modernization and industrialization. He is in charge of and is part of several scientific researches and major projects, which bring great financial, environmental and social benefits to the industry.

You can access his presentation here.

lic. Iur. Attorney-at-Law

After completing his studies in law at the universities of Lausanne and Fribourg and training his English in London, Jürg Granwehr worked for some years in the Swiss court system before joining a leading health insurance group, where he held the position of Head of Insurance Law for several years. Working since more than six years for various national industrial associations, at present Jürg Granwehr is Head of Pharma at scienceindustries. In this function, he is the secretary of the Board Committee on Pharmaceutical Affairs and responsible for all activities in that field. He aims to coordinate the positions among the different associations of the pharmaceutical industry in Switzerland and plays an active part in a range of working groups, for example in regulatory affairs, clinical research or veterinary pharmaceuticals. As chairman of the Swiss Code Committee Jürg Granwehr holds a key position in the implementation of the Pharma self-regulation in Switzer- land and surveys the Code Secretariat. In addition, he tracks and handles all legal issues of overall importance to the life science industry (e.g. data policy and protection, corporation law, labor law, statute of limitations etc.). He participates in the relevant committees of economiesuisse (especially its Legal Commission and subgroups), acts as secretary of the relevant working groups within scienceindustries, regularly prepares reports to the attention of the Board Committee on Economic Affairs and represents these concerns of the life science industry in the political process.

You can access his presentation here.

Born in July, 1973. He majored in Polymer Chemistry at Fudan University, and obtained the degree of MPAcc from a joint program by Shanghai National Accounting Institute and Shanghai University of Finance and Economics. As an economist, he is now the Vice President of Shanghai Pharmaceuticals Holding Co., Ltd. (SPH), Chairman of Shanghai Zhongxi Sunve Pharmaceutical Co., Ltd., Director of SPH Sino-biopharma, Director of SPHSALES, Director of Shanghai Sunve Co., Ltd., Chairman of Shangyao Kony (Changzhou) Pharmaceutical Co., Ltd., Chairman of SPH (Dali) Taxaceae-Bio Co., Ltd., Chairman of Shanghai Tsumura Pharmaceutical Co., Ltd., and Chairman of Shanghai SPH Tsumura Pharmaceutical Technology Co., Ltd. He previously served as the Director of SPH, the General Manager of Strategy and Investment Development Department, the Vice General Manager of Shanghai Zhongxi Sunve Pharmaceutical Co., Ltd., CFO of Shanghai New Hualian Pharmaceutical Co., Ltd., CFO of API Department of SPH, etc.

You can access his presentation here.

After his studies of Administration Sciences at the University of Constance in Germany, Andreas M. Walter joined EFPIA, the European Federation of the researched-based pharmaceutical industry, in September 1993 as Executive for Administration and Finance. From 2011 onwards, he was responsible as Project Director to ensure that EFPIA members can comply with the safety features requirements of the Falsified Medicines Directive in the most effective way, i.e. by setting up of a stakeholder-governed pan-European verification model (EMVS). After the incorporation of the European Medicines Verification Organisation (EMVO) in February 2015, he also headed the organisation ad interim in order to manage the European hub that will connect to a series of national data repositories serving as the platform to allow the verification of authenticity of medicines anywhere in the supply chain within the EU/EEA. On 1^st April 2016, he was appointed as General Manager of EMVO representing now definitely the organisation.  

You can access his presentation here.

Faraz Kermani has over 16 years experience in journalism and 9 years in communications. He is a former Communications Manager (External Affairs) at EFPIA and prior to this worked for the European Generic medicines Association (now Medicines for Europe) and a senior- UK-based health communications agency. As a journalist he has written for a number of high profile publications, including Scrip, the Regulatory Affairs Journal and The Pink Sheet. He holds a Master’s Degree in European Law from King’s College London and a Bachelor’s from University College London in German and Scandinavian Studies.